A

AdvanCell

Manufactures Lead-212 for targeted alpha therapy

Senior Translational Scientist

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeBrisbane QLD, AustraliaNo salary listedIn-person

About the Job

Requirements

  • A PhD in Biology, Cancer Biology, Pharmacology, Biochemistry, Molecular Biology, or another relevant life-sciences discipline is required.
  • Demonstrated experience designing and leading preclinical oncology research programs within academia, biotechnology, or the pharmaceutical industry.
  • Extensive hands-on experience conducting in vitro and in vivo studies, including murine tumour models and associated animal procedures.
  • Strong knowledge of molecular and cellular biology techniques relevant to translational cancer research, such as flow cytometry, quantitative polymerase chain reaction, Western blotting, immunohistochemistry, and tissue culture.
  • Experience analysing complex scientific data using appropriate statistical methods and communicating findings through reports, presentations, and publications.
  • Demonstrated experience managing multiple research projects, prioritising competing activities, and delivering outcomes to agreed timelines.
  • Experience supervising, mentoring, and developing junior scientists or research staff.
  • Strong understanding of regulatory expectations, including Good Laboratory Practice, animal ethics, scientific documentation, and non-clinical data supporting drug development.
  • Experience in a biotechnology, pharmaceutical, or radiopharmaceutical environment, exposure to preclinical imaging technologies, regulatory submissions such as IND/CTA, targeted radionuclide therapies, scientific publications, patents or grant applications, and possession of or eligibility to obtain a Queensland Radiation Use Licence are highly regarded.

Responsibilities

  • Design, plan, and execute high-quality in vitro, ex vivo, and in vivo preclinical studies to support development of targeted radiopharmaceutical therapies.
  • Lead the design, optimisation, and execution of preclinical assays, including target validation, efficacy, biodistribution, pharmacology, and toxicity studies.
  • Analyse, interpret, and present experimental data, preparing technical reports, presentations, and scientific documentation to support project decisions.
  • Prepare and contribute to non-clinical documentation for regulatory submissions, investigator brochures, publications, patents, and scientific presentations.
  • Lead and coordinate preclinical research projects, ensuring studies are delivered on time, to budget, and in accordance with project objectives.
  • Mentor, train, and provide technical guidance to scientists, research assistants, and students.
  • Collaborate with Discovery, Isotope Development, Manufacturing, Clinical Development, and external research partners to progress translational research programs.
  • Ensure research activities comply with Good Laboratory Practice, Standard Operating Procedures, animal ethics requirements, radiation safety regulations, and company quality systems.
  • Identify opportunities to improve experimental design, laboratory practices, data quality, and operational efficiency.
  • Maintain accurate scientific records and contribute to maintaining laboratory equipment, facilities, and resources.

About the Company

AdvanCell

Manufactures Lead-212 for targeted alpha therapy

AdvanCell develops radiopharmaceuticals for targeted alpha therapy, using Lead-212 and an on-demand Alpha Isotope Generator to produce the isotope daily. Its core product ADVC-001 targets PSMA to treat metastatic castration-resistant prostate cancer, evaluated in the multicenter TheraPb Phase I/II trial, while the company also pipelines other cancer therapies. The approach combines isotope production, drug manufacturing, and clinical development in a vertically integrated model to ensure reliable supply and faster development. Its goal is to speed patient access to radiopharmaceutical treatments by expanding its portfolio through collaborations, including a strategic partnership with Eli Lilly, and advancing clinical trials.

Company size
51-200
Company stage
Series D
Total funding
$440.8M
Headquarters
Sydney NSW, Australia
Founded
2019

Recently Posted Jobs

Explore more opportunities at AdvanCell

See more jobs